Erytech Pharma SA has teamed up with SQZ Biotechnologies Co, a spin-out of the Massachusetts Institute of Technology, to develop antigen-specific immune modulating therapies for cancer. The collaboration uses Erytech’s technique for encapsulating drug substances inside red blood cells to inform drug development by SQZ. The MIT spin-out is a cell therapy company.
